tetano
Editor, Senior Moderator
Inflamm Bowel Dis. 2020 May 12. pii: izaa109. doi: 10.1093/ibd/izaa109. [Epub ahead of print]
Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature.
Rosen MH[SUP]1[/SUP], Axelrad J[SUP]1[/SUP], Hudesman D[SUP]1[/SUP], Rubin DT[SUP]2[/SUP], Chang S[SUP]1[/SUP].
Author information
Abstract
First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.
? 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; coronavirus; cyclosporine; inflammatory bowel disease; pregnancy; ulcerative colitis
PMID:32393973DOI:10.1093/ibd/izaa109
Management of Acute Severe Ulcerative Colitis in a Pregnant Woman With COVID-19 Infection: A Case Report and Review of the Literature.
Rosen MH[SUP]1[/SUP], Axelrad J[SUP]1[/SUP], Hudesman D[SUP]1[/SUP], Rubin DT[SUP]2[/SUP], Chang S[SUP]1[/SUP].
Author information
Abstract
First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.
? 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
KEYWORDS:
COVID-19; coronavirus; cyclosporine; inflammatory bowel disease; pregnancy; ulcerative colitis
PMID:32393973DOI:10.1093/ibd/izaa109